The DOI matches its Crossref record.
Long‐term surveillance of SUDEP in drug‐resistant epilepsy patients treated with VNS therapy
Open accessAbstract
Summary: Objective: Limited data are available regarding the evolution over time of the rate of sudden unexpected death in epilepsy patients (SUDEP) in drug‐resistant epilepsy. The objective is to analyze a database of 40 443 patients with epilepsy implanted with vagus nerve stimulation (VNS) therapy in the United States (from 1988 to 2012) and assess whether SUDEP rates decrease during the postimplantation follow‐up period. Methods: Patient vital status was ascertained using the Centers for Disease Control and Prevention's National Death Index (NDI). An expert panel adjudicated classification of cause of deaths as SUDEP based on NDI data and available narrative descriptions of deaths. We tested the hypothesis that SUDEP rates decrease with time using the Mann‐Kendall nonparametric trend test and by comparing SUDEP rates of the first 2 years of follow‐up (years 1‐2) to longer follow‐up (years 3‐10). Results: Our cohort included 277 661 person‐years of follow‐up and 3689 deaths, including 632 SUDEP. Primary analysis demonstrated a significant decrease in age‐adjusted SUDEP rate during follow‐up (S = −27 P = .008), with rates of 2.47/1000 for years 1‐2 and 1.68/1000 for years 3‐10 (rate ratio 0.68; 95% confidence interval [CI] 0.53‐0.87; P = .002). Sensitivity analyses confirm these findings. Significance: Our data suggest that SUDEP risk significantly decreases during long‐term follow‐up of patients with refractory epilepsy receiving VNS Therapy. This finding might reflect several factors, including the natural long‐term dynamic of SUDEP rate, attrition, and the impact of VNS Therapy. The role of each of these factors cannot be confirmed due to the limitations of the study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Thijs, R. D., Surges, R., O'Brien, T. J., & Sander, J. W. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32596-0 · Cited by 2,183
Devinsky, O., Vezzani, A., O'Brien, T. J., Jette, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 959
Self-citationSalanova, V., Sperling, M. R., Gross, R. E., Irwin, C. P., Vollhaber, J. A., Giftakis, J. E., Fisher, R. S., & SANTÉ Study Group (2021) · Epilepsia · doi:10.1111/epi.16895 · Cited by 333
Self-citationClinical risk factors in SUDEP: A nationwide population-based case-control study
Sveinsson, O., Andersson, T., Mattsson, P., Carlsson, S., & Tomson, T. (2020) · Neurology · doi:10.1212/wnl.0000000000008741 · Cited by 330
Neuromodulation in epilepsy: state-of-the-art approved therapies
Ryvlin, P., Rheims, S., Hirsch, L. J., Sokolov, A., & Jehi, L. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00300-8 · Cited by 314
Self-citation
Metadata
- Authors
- Ryvlin, P., So, E. L., Gordon, C. M., Hesdorffer, D. C., Sperling, M. R., Devinsky, O., Bunker, M. T., Olin, B., & Friedman, D.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2018-01-16
- Volume
- 59
- Issue
- 3
- Pages
- 562-572
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2783075047
- Cited by
- 159
- References
- 0
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term surveillance of SUDEP in drug‐resistant epilepsy patients treated with VNS therapy. https://app.cochat.ai/papers/10.1111/epi.14002
- The paper
- Ryvlin, P., So, E. L., Gordon, C. M., Hesdorffer, D. C., Sperling, M. R., Devinsky, O., Bunker, M. T., Olin, B., & Friedman, D. (2018). Long‐term surveillance of SUDEP in drug‐resistant epilepsy patients treated with VNS therapy. Epilepsia. https://doi.org/10.1111/epi.14002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.